Protara Therapeutics, Inc.
TARA
$3.44
-$0.08-2.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.28% | -4.95% | -12.65% | -10.59% | -6.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.63% | 15.23% | -12.18% | 21.77% | 10.50% |
| Operating Income | -29.63% | -15.23% | 12.18% | -21.77% | -10.50% |
| Income Before Tax | -24.93% | -13.78% | 15.77% | -22.66% | 73.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.93% | -13.78% | 15.77% | -22.66% | 73.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.93% | -13.78% | 15.77% | -22.66% | 73.77% |
| EBIT | -29.63% | -15.23% | 12.18% | -21.77% | -10.50% |
| EBITDA | -30.14% | -15.30% | 12.30% | -21.89% | -10.26% |
| EPS Basic | 46.28% | 42.18% | 55.15% | -21.41% | 74.00% |
| Normalized Basic EPS | 46.29% | 42.18% | 55.14% | -21.42% | -7.23% |
| EPS Diluted | 46.28% | 42.18% | 55.15% | -21.41% | 74.00% |
| Normalized Diluted EPS | 46.29% | 42.18% | 55.14% | -21.42% | -7.23% |
| Average Basic Shares Outstanding | 132.58% | 96.77% | 87.77% | 1.04% | 0.87% |
| Average Diluted Shares Outstanding | 132.58% | 96.77% | 87.77% | 1.04% | 0.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |